Zhi Tong Cai Jing·2025-07-30 03:26Core Viewpoint - Baiyunshan (00874) has seen a nearly 3% increase in stock price, currently at HKD 18.62, following the announcement of a partnership agreement with Guangzhou Pharmaceutical Capital to establish a second phase of the Guangzhou Pharmaceutical Fund [1] Group 1: Company Actions - Baiyunshan will invest RMB 1.4985 billion and Guangzhou Pharmaceutical Capital will invest RMB 1.5 million in the establishment of the Guangzhou Pharmaceutical Fund Phase II [1] - The company will have substantial control over the fund, and its financial performance will be included in the company's consolidated financial statements [1] Group 2: Investment Focus - The partnership aims to conduct equity investments in the biopharmaceutical sector, focusing on generating investment returns [1] - The investment strategy will align with the company's strategic planning, targeting areas such as pharmaceuticals, medical devices, and healthcare services within the biopharmaceutical and health sectors [1] Group 3: Strategic Goals - The establishment of the Guangzhou Pharmaceutical Fund Phase II is intended to seize industry development opportunities and accelerate the company's layout in the biopharmaceutical health sector [1] - The initiative will enhance the company's efforts in incubating and investing in the pharmaceutical health industry [1]